Target intelligence / Profile preview

Flotillin-2 (FLOT2)

Target
FLOT2
Molecular classification
Scaffolding protein, Lipid raft-associated protein, Stomatin/prohibitin/flotillin/HflK/C (SPFH) superfamily member, Other
01

Overview

Flotillin-2 is a membrane-associated scaffolding protein of the SPFH superfamily, functioning as a principal component of lipid raft microdomains. It is ubiquitously expressed in mammalian cells and plays a critical role in organizing multiprotein complexes at the plasma membrane and endomembranes. Flotillin-2, often together with flotillin-1, facilitates clathrin-independent endocytosis, cell signaling, and protein trafficking by forming large oligomeric complexes—sometimes described as basket- or cage-like structures—that isolate and coordinate localized biochemical processes. Its membrane attachment is regulated through *N*-myristoylation and *S*-palmitoylation, contributing to its association with cholesterol- and sphingolipid-rich raft domains. Flotillin-2 is implicated in cancer progression, neurodegenerative diseases, and possibly immunological and infectious pathologies, largely owing to its role in membrane dynamics, signaling, and vesicular transport.

Other names
Flotillin-2FLOT2ESA1M17S1ESAECS-1ECS1Epidermal surface antigenMembrane component chromosome 17 surface marker 1Flotillin 2 (epidermal surface antigen 1)membrane component, chromosome 17, surface marker 1 (35kD protein identified by monoclonal antibody ECS-1)
02

Mechanism of action

Not directly targeted pharmacologically; proposed mechanisms involve disruption of flotillin-2 oligomerization or membrane association to block its scaffolding function (hypothetical, preclinical context).

03

Biological functions

Membrane organizationEndocytosis (primarily clathrin-independent pathway)Cell signalingProtein traffickingAssembly of multiprotein complexesCell migration
04

Disease associations

Cancer (oncogenic signaling, cancer cell migration and invasion)Neurodegenerative disease (role in endocytosis and trafficking)Other (potential involvement in infection, inflammation)
05

Safety considerations

No drugs specifically target flotillin-2; however, due to its ubiquitous cellular roles, inhibition could disrupt fundamental membrane trafficking and signaling processes, affecting normal cell function.
06

Interacting drugs

None established; no approved or clinical drugs principally target flotillin-2 directly (as of 2024).
07

Biomarkers

Flotillin-2 expression (useful as a biomarker in some cancer subtypes, e.g. to reflect invasiveness or disease progression)

Beyond the preview

Go deeper on Flotillin-2 (FLOT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flotillin-2 (FLOT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call